Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 8, 2017Top-line Phase 1 Selinexor Data in Combination with Chemotherapy Show Encouraging Early Efficacy in Patients with Ovarian and Endometrial Cancers
NEWTON, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the...
-
Aug 30, 2017
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Aug 30, 2017
NEWTON, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two upcoming poster presentations at the...
-
Aug 8, 2017− Pivotal Phase 3 BOSTON Study Underway -
NEWTON, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2017...
-
Aug 1, 2017
NEWTON, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2017...
-
Jun 23, 2017Objective Response Rate Increases to 33.3% Overall and is 35% in Patients with "Double- or Triple-Hit" DLBCL
NEWTON, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported updated clinical data from the ongoing Phase 2b...
-
Jun 7, 2017
NEWTON, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in its pivotal...
-
May 31, 2017
NEWTON, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...
-
May 18, 2017
NEWTON, Mass., May 18, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that interim clinical data from the ongoing...
-
May 4, 2017− Pivotal Phase 3 BOSTON Study Expected to Commence in May 2017 —
NEWTON, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2017 and...
-
May 3, 2017− Anivive Aims to Develop and Commercialize Verdinexor for the Treatment of Cancer in Companion Animals —
NEWTON, Mass., May 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, and Anivive Lifesciences, a privately-held biotech company...
-
Apr 27, 2017
NEWTON, Mass., April 27, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2017...
-
Apr 25, 2017
NEWTON, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of a registered underwritten...
-
Apr 24, 2017
NEWTON, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it is commencing a registered...
-
Apr 4, 2017Selinexor Achieves Robust and Prolonged Response Rates in Patients with Relapsed or Refractory DLBCL, Including Against Both GCB and Non-GCB Subtypes
NEWTON, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced that updated interim clinical data from its Phase...
-
Apr 3, 2017
NEWTON, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin Renz, Executive Vice President,...
-
Mar 31, 2017Abstract Published Today Highlighting Interim Phase 2b SADAL Results in Patients with Relapsed or Refractory DLBCL
NEWTON, Mass., March 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that interim clinical data from its Phase 2b...
-
Mar 30, 2017Recruitment Resumes Across All Selinexor Trials in Hematological Malignancies
NEWTON, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
-
Mar 29, 2017
NEWTON, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Mar 16, 2017− Overall Response Rate of 28.4% Observed in Phase 2b SADAL Study in Relapsed/Refractory DLBCL; Additional Top-line Data to be Presented as a Late-Breaker at AACR 2017 Annual Meeting —
NEWTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and...
-
Mar 10, 2017All Currently Enrolled Patients with Stable Disease or Better Can Continue Receiving Selinexor
NEWTON, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has received written notice from the...
-
Mar 9, 2017
NEWTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year...
-
Mar 2, 2017Study Will Not Reach Statistically Significant Improvement in Primary Endpoint of Overall Survival in Patients who are Unfit for Chemotherapy and/or Transplantation; Patients Deriving Benefit to Remain on Study
NEWTON, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the results of a planned interim analysis of...
-
Mar 1, 2017Late-Breaking Presentation Highlighting Interim Phase 2b Selinexor Data in Patients with Relapsed or Refractory DLBCL (SADAL Study)
NEWTON, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 12 abstracts describing the Company's...
-
Jan 31, 2017
NEWTON, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Jan 3, 2017
NEWTON, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Dec 15, 2016- Target ALS Consortium Grants $900,000 in Research Funding for KPT-350 in ALS -
NEWTON, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Target ALS Foundation, a non-profit...
-
Dec 5, 2016- STOMP Data Continues to Demonstrate High Response Rates in Patients with Heavily Pretreated Multiple Myeloma When Selinexor Is Combined with Bortezomib and Pomalidomide -
NEWTON, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from the Phase 1b...
-
Dec 4, 2016- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia -
NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from the Phase 2 SAIL study,...
-
Dec 4, 2016- Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -
NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced updated results from its Phase 2b STORM study...
-
Nov 30, 2016
NEWTON, Mass. and NORWALK, Conn., Nov. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, together with the Multiple Myeloma Research...
-
Nov 10, 2016
NEWTON, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Nov 7, 2016− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout —
NEWTON, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2016...
-
Nov 3, 2016- Diverse Data Continue to Reinforce the Efficacy and Safety of Selinexor in Patients with Heavily Pretreated Refractory Multiple Myeloma -
NEWTON, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 21 abstracts have been selected for...
-
Nov 2, 2016
NEWTON, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that company executives, including founder...
-
Oct 31, 2016
NEWTON, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2016...
-
Oct 11, 2016
NEWTON, Mass., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Justin A. Renz, Executive Vice President,...
-
Oct 5, 2016- Single-Agent Selinexor Demonstrates Robust Clinical Benefit and Favorable Tolerability in Patients with Heavily Pre-treated Gynecologic Cancers -
NEWTON, Mass., Oct. 05, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that an oral presentation highlighting updated...
-
Sep 29, 2016- Nuclear Transport Machinery Identified as a Necessary and Universal Driver of KRAS-mutant Cell Survival -
NEWTON, Mass., Sept. 29, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that preclinical data describing XPO1...
-
Sep 28, 2016- XPO1 Inhibition Significantly Reduced Tumor Burden in Platinum Sensitive and Resistant Ovarian Cancer Models-
NEWTON, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that preclinical and Phase 1 clinical data...
-
Sep 12, 2016
NEWTON, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Humphrey A.R. Gardner MD,...
-
Sep 6, 2016- Selinexor Achieves Promising Response Rates in Patients with Multiple Myeloma, Including 20.8% in Quad-Refractory and 20.0% in Penta-Refractory Disease -
NEWTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from its Phase 2b...
-
Aug 30, 2016
NEWTON, Mass., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced it will provide an overview of top-line...
-
Aug 4, 2016Completed Enrollment in Phase 2b STORM Clinical Trial for Refractory Multiple Myeloma
NEWTON, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2016...
-
Aug 3, 2016
NEWTON, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Jul 28, 2016
NEWTON, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2016...
-
Jul 27, 2016Data Provide Early Evidence of Anticancer Activity in Advanced Sarcoma and Inform Recommended Phase 2 Dose
NEWTON, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that data from its Phase 1b clinical trial...
-
Jul 27, 2016- Oral Presentation Describing Efficacy of Selinexor in Gynecological Cancers -
NEWTON, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three abstracts have been selected for...
-
Jul 6, 2016
NEWTON, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief...
-
Jun 22, 2016
NEWTON, Mass., June 22, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced dosing of the first patient in a Phase 1...